{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/covid-19/","result":{"pageContext":{"chapter":{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field f7639692-6f54-4532-abb7-ab9c00bb9bd3 --><h2>Scenario: COVID-19 Management</h2><!-- end field f7639692-6f54-4532-abb7-ab9c00bb9bd3 -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item 6917e746-85da-4ccb-b924-ab9c00bb9b3b --><!-- begin field fc563fca-8f84-4d03-80b2-acbc015c27ab --><p>From age 18 years onwards.</p><!-- end field fc563fca-8f84-4d03-80b2-acbc015c27ab --><!-- end item 6917e746-85da-4ccb-b924-ab9c00bb9b3b -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3f344405-5c35-55cb-913f-946eaf29b1d3","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 8cef84f7-840a-4f55-8590-ab9c00bb9bd4 --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 8cef84f7-840a-4f55-8590-ab9c00bb9bd4 -->","summary":null,"htmlStringContent":"<!-- begin item e4705857-75b4-4fda-9524-ab9c00bb9bd4 --><!-- begin field 4e78ab1b-7196-4d37-ad86-ab9c00bb9bd4 --><ul><li>In people with rheumatoid disease with <strong>known or suspected to have COVID‑19</strong>, the recommendations are that they should:<ul><li>Continue hydroxychloroquine and sulfasalazine.</li><li>Not suddenly stop prednisolone.</li><li>Only have corticosteroid injections if the person has significant disease activity and there are no alternatives, and discuss with their specialist before doing so.</li><li>Temporarily stop other disease-modifying antirheumatic drugs, JAK inhibitors, and biological therapies, and tell them to contact their rheumatology department for advice on when to restart treatment.</li></ul></li></ul><h4>Management of other therapies for asymptomatic people</h4><ul><li><strong>Nonsteroidal anti-inflammatory drugs</strong><ul><li>Advise patients taking a nonsteroidal anti-inflammatory drug for a long-term condition such as rheumatoid arthritis that it does not need to be stopped.</li></ul></li><li><strong>Corticosteroids</strong><ul><li>Advise patients taking prednisolone that it should not be stopped suddenly. They may wish to discuss lowering their dose in consultation with their specialist.</li></ul></li><li><strong>Biological treatments</strong><ul><li>These people may be assessed and moved from intravenous treatments to subcutaneous or from subcutaneous to oral treatments. They may also have the duration periods between treatments increased.</li></ul></li><li><strong>Immunoglobulins</strong><ul><li>People on this therapy may have the duration periods between treatments increased.</li></ul></li><li><strong>Bisphosphonates and denosumab</strong><ul><li>Do not postpone treatment with denosumab.</li></ul></li><li><strong>Zoledronate</strong><ul><li>Note that treatment with zoledronate can be postponed for up to 6 months.</li></ul></li></ul><h4>Drug monitoring</h4><ul><li>Patients starting a new disease-modifying antirheumatic drug should follow recommended blood monitoring guidelines. When this is not possible, they should contact the relevant specialist for advice.</li><li>In consultation with their specialist, each person may be able to safely increase the time interval between blood tests for drug monitoring, particularly if 3‑monthly blood tests have been stable for more than 2 years.</li></ul><!-- end field 4e78ab1b-7196-4d37-ad86-ab9c00bb9bd4 --><!-- end item e4705857-75b4-4fda-9524-ab9c00bb9bd4 -->","subChapters":[{"id":"b2e07030-98be-5861-b122-d068e2b00f45","slug":"basis-for-recommendation-de8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 97770977-c22a-4481-a667-ab9c00bb9bd6 --><h4>Basis for recommendation</h4><!-- end field 97770977-c22a-4481-a667-ab9c00bb9bd6 -->","summary":null,"htmlStringContent":"<!-- begin item de88ed18-bf7f-4768-897c-ab9c00bb9bd6 --><!-- begin field 7ab70d9c-1318-47f7-9eb9-ab9c00bb9bd6 --><p>These recommendations are based on <em>COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NICE, 2020</a>].</p><!-- end field 7ab70d9c-1318-47f7-9eb9-ab9c00bb9bd6 --><!-- end item de88ed18-bf7f-4768-897c-ab9c00bb9bd6 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}